What is Kerecis?
Headquartered in the Westfjords of Iceland, Kerecis specializes in the development of medical devices derived from fish skin to facilitate the healing of complex wounds and tissue damage. The company's core technology utilizes the natural structure of fish skin, which is highly compatible with human tissue, to provide a scaffold that promotes rapid regeneration and reduces the risk of infection. This unique approach positions Kerecis at the intersection of biotechnology and advanced wound management, offering a sustainable and highly effective alternative to synthetic or mammalian-derived products. As the company scales, it continues to build a robust portfolio of clinical evidence, solidifying its market position as a critical provider in the global healthcare supply chain.
How much funding has Kerecis raised?
Kerecis has raised a total of $145M across 6 funding rounds:
Series A
$2M
Series B
$3M
Debt
$3M
Series C
$16M
Debt
$21M
Series D
$100M
Series A (2014): $2M with participation from EHF Capital and New Business Venture Fund
Series B (2016): $3M, investors not publicly disclosed
Debt (2018): $3M, investors not publicly disclosed
Series C (2019): $16M featuring Undisclosed
Debt (2020): $21M backed by Silicon Valley Bank
Series D (2022): $100M with participation from Kirkbi and Emerson Collective
Key Investors in Kerecis
Kirkbi
Kirkbi is a private holding and investment company that manages the long-term interests of the LEGO brand, focusing on sustainable investments across renewable energy and strategic corporate sectors.
Emerson Collective
Emerson Collective is a purpose-driven investment firm that supports innovators tackling complex global challenges in education, environment, and human health.
Silicon Valley Bank
Silicon Valley Bank is a specialized financial institution providing commercial banking and investment services tailored to the unique needs of the technology and life sciences sectors.
What's next for Kerecis?
With the recent infusion of capital, Kerecis is well-positioned to scale its commercial operations and deepen its penetration into international markets. The strategic focus will likely shift toward expanding clinical applications for its fish skin technology, potentially targeting new therapeutic areas beyond traditional wound care. Furthermore, the company is expected to invest heavily in manufacturing infrastructure to meet the growing global demand for its regenerative products. By maintaining its commitment to rigorous research and development, Kerecis aims to set new standards in tissue repair, ensuring long-term value creation for its stakeholders and improved patient outcomes worldwide.
See full Kerecis company page
